Question 1

Why do nearly 50% of drug launches underperform despite years of clinical development?

Accepted Answer

Many drug launches fail to meet expectations because of the "innovation readiness gap" within healthcare systems. While a drug may receive regulatory approval based on clinical trial data, hospitals may not be equipped to implement the new treatment, such as having the necessary diagnostic biomarkers or specific imaging schedules in place. Additionally, the competitive window in fields like oncology has shrunk significantly, leaving companies less time to establish their product before competitors enter the market.

Question 2

What is the "Early Asset Strategy Team" (EAST) and why is it necessary?

Accepted Answer

The EAST model involves embedding Medical Affairs into the drug development process long before Phase 3 results are available. This shift is necessary because waiting for approval to understand the healthcare ecosystem is no longer viable. By mapping the patient journey and identifying system gaps years in advance, Medical Affairs can ensure that clinical trials gather the specific data that payers and physicians actually care about, rather than just meeting regulatory requirements.

Question 3

How does Medical Affairs identify the right experts to engage with during a launch?

Accepted Answer

Modern Medical Affairs avoids "targeting by fame" and instead segments experts by their specific function within the ecosystem. They categorize influencers into three buckets: Evidence Shapers, who influence trial design; Operational Accelerators, who manage clinical sites and patient recruitment; and Safety Guardians, who shape the perception of risk and management protocols. They also track Digital Opinion Leaders (DOLs) who influence medical sentiment online and "Rising Stars" who represent the future of the field.

Question 4

What is the "3-layer question stack" used by Medical Science Liaisons (MSLs)?

Accepted Answer

The 3-layer question stack is a communication framework designed to move away from one-way presentations toward consultative problem-solving. It begins with a "Reality Check" to understand the practical challenges a doctor faces, followed by a "Mechanism" question to identify the root cause of those challenges. It concludes with a "Mitigation" question, which invites the healthcare provider to co-design a solution, effectively turning the MSL into a strategic partner rather than a salesperson.

Question 5

How is the success of Medical Affairs measured if they cannot use sales targets?

Accepted Answer

Since Medical Affairs must remain unbiased and scientifically credible, they use "Impact KPIs" and qualitative indicators rather than sales numbers. Success is measured by the quality of actionable insights gathered from the field, the closure of specific evidence gaps through Real-World Evidence (RWE) or Investigator-Initiated Studies (IIS), and shifts in the medical community’s sentiment and advocacy over time. This "Scientific Reputation Score" reflects their ability to change how a disease is managed.

Medical Affairs: The Mission Control for Oncology Launches

How This Personalized Podcast Was Made

More like this